382 results on '"Díaz Rubio M"'
Search Results
2. Regular Consumption of an Antioxidant-rich Juice Improves Oxidative Status and Causes Metabolome Changes in Healthy Adults
- Author
-
Díaz-Rubio, M. Elena, Pérez-Jiménez, Jara, Martínez-Bartolomé, Miguel Ángel, Álvarez, Inmaculada, and Saura-Calixto, Fulgencio
- Published
- 2015
- Full Text
- View/download PDF
3. Contributors
- Author
-
Bährs, Hanno, primary, Borczak, Barbara, additional, Caboni, Maria Fiorenza, additional, Campillo, Natalia, additional, Carle, Reinhold, additional, Chakrabarti, Shumon, additional, Dannehl, Dennis, additional, Díaz-Rubio, M Elena, additional, Fernández-Gutiérrez, Alberto, additional, Galili, Shmuel, additional, Gómez-Caravaca, Ana Maria, additional, Hovav, Ran, additional, Jáuregui, Olga, additional, Josuttis, Melanie, additional, Kammerer, Judith, additional, Kammerer, Dietmar Rolf, additional, Kontogianni, Vassiliki G., additional, Lamuela-Raventós, Rosa María, additional, Laue, Pauline, additional, Libuy, Matías, additional, Martínez-Huélamo, Miriam, additional, Pérez-Jiménez, Jara, additional, Quifer-Rada, Paola, additional, Rodrigo, Ramón, additional, Ruberto, Giuseppe, additional, Sabatino, Leonardo, additional, Salib, Josline Y., additional, Saura-Calixto, Fulgencio, additional, Schieber, Andreas, additional, Schulze-Kaysers, Nadine, additional, Scordino, Monica, additional, Segura-Carretero, Antonio, additional, Shrestha, Gajendra, additional, Sikora, Elżbieta, additional, Siracusa, Laura, additional, St Clair, Larry L., additional, Steinberg, Christian E.W., additional, Vallverdú-Queralt, Anna, additional, Verardo, Vito, additional, Viñas, Pilar, additional, and Weber, Fabian, additional
- Published
- 2014
- Full Text
- View/download PDF
4. Non-Extractable Polyphenols in Plant Foods
- Author
-
Pérez-Jiménez, Jara, primary, Díaz-Rubio, M Elena, additional, and Saura-Calixto, Fulgencio, additional
- Published
- 2014
- Full Text
- View/download PDF
5. Effects of grape antioxidant dietary fiber in cardiovascular disease risk factors
- Author
-
Jiménez, Jara Pérez, Serrano, Jose, Tabernero, Maria, Arranz, Sara, Díaz-Rubio, M. Elena, García-Diz, Luis, Goñi, Isabel, and Saura-Calixto, Fulgencio
- Published
- 2008
- Full Text
- View/download PDF
6. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility
- Author
-
Cénit, M C, Alcina, A, Márquez, A, Mendoza, J L, Díaz-Rubio, M, de las Heras, V, Izquierdo, G, Arroyo, R, Fernández, O, de la Concha, E G, Matesanz, F, and Urcelay, E
- Published
- 2010
- Full Text
- View/download PDF
7. Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility
- Author
-
Márquez, A, Cénit, M C, Núñez, C, Mendoza, J L, Taxonera, C, Díaz-Rubio, M, Bartolomé, M, Arroyo, R, Fernández-Arquero, M, de la Concha, E G, and Urcelay, E
- Published
- 2009
- Full Text
- View/download PDF
8. Bioavailability of Phenolic Antioxidants Associated with Dietary Fiber: Plasma Antioxidant Capacity After Acute and Long-Term Intake in Humans
- Author
-
Pérez-Jiménez, Jara, Serrano, José, Tabernero, Maria, Arranz, Sara, Díaz-Rubio, M. Elena, García-Diz, Luis, Goñi, Isabel, and Saura-Calixto, Fulgencio
- Published
- 2009
- Full Text
- View/download PDF
9. FRUIT MACROANTIOXIDANTS, A NEW TYPE OF MAJOR PLANT FOOD CONSTITUENTS, SIGNIFICANTLY CONTRIBUTE TO THE INTAKE OF ANTIOXIDANTS IN THE DIET: O106
- Author
-
Pérez-Jiménez, J., Díaz-Rubio, M E., and Saura-Calixto, F.
- Published
- 2013
10. MYO9B polymorphisms in patients with inflammatory bowel disease
- Author
-
Núñez, C, Oliver, J, Mendoza, J L, Gómez-García, M, Piñero, A, Taxonera, C, Díaz-Rubio, M, López-Nevot, M A, de la Concha, E G, Nieto, A, Urcelay, E, Martínez, A, and Martín, J
- Published
- 2007
11. Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD
- Author
-
Martínez, A., Núñez, C., Martín, M. C., Mendoza, J. L., Taxonera, C., Díaz-Rubio, M., de la Concha, E. G., and Urcelay, E.
- Published
- 2007
12. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study)
- Author
-
GARRIGUES, V., MEARIN, F., BADÍA, X., BALBOA, A., BENAVENT, J., CABALLERO, A., DOMÍNGUEZ, E., DÍAZ-RUBIO, M., ROSET, M., FIGUERAS, M., and CUCALA, M.
- Published
- 2007
13. Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
- Author
-
Mendoza, J. L., Lana, R., Díaz-Rubio, M., de la Concha, E. G., and Urcelay, E.
- Published
- 2007
14. Leflunomide-induced acute hepatitis
- Author
-
Sevilla-Mantilla, C., Ortega, L., Agúndez, J.A.G., Fernández-Gutiérrez, B., Ladero, J.M., and Dı́az-Rubio, M.
- Published
- 2004
- Full Text
- View/download PDF
15. Effects of effervescent ranitidine on gastric pH: comparison with almagate and placebo in fasting and postprandial conditions
- Author
-
REY, E., POVES-FRANCÉS, C., SÁNCHEZ, G., FUEYO, A., BADIOLA, C., and DÍAZ-RUBIO, M.
- Published
- 2004
16. Prevalence of Mutations of the NOD2/CARD15 Gene and Relation to Phenotype in Spanish Patients with Crohn Disease
- Author
-
Mendoza, J. L., Murillo, L. S., Fernández, L., Peña, A. S., Lana, R., Urcelay, E., Cruz-Santamaría, D. M., de la Concha, E. G., Díaz-Rubio, M., and García-Paredes, J.
- Published
- 2003
17. RsaI Polymorphism at the CYP2E1 Locus and Risk of Primary Liver Cancer: PI-21
- Author
-
Benítez, J., Agúndez, J.A. G., Ladero, J. M., Rodriguez-Lescure, A., and Díaz-Rubio, M.
- Published
- 1996
18. Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer
- Author
-
Ladero, J. M., Benítez, J., González, J. F., Vargas, E., and Díaz-Rubio, M.
- Published
- 1991
- Full Text
- View/download PDF
19. Regular Consumption of an Antioxidant-rich Juice Improves Oxidative Status and Causes Metabolome Changes in Healthy Adults
- Author
-
Díaz Rubio, M. Elena, Pérez-Jiménez, Jara, Martínez-Bartolomé, Miguel A., Álvarez Acero, Inmaculada, Díaz Rubio, M. Elena, Pérez-Jiménez, Jara, Martínez-Bartolomé, Miguel A., and Álvarez Acero, Inmaculada
- Abstract
An improvement in oxidative status is associated with a reduction in the incidence of several chronic diseases. However, daily intake of antioxidants in Western diets is decreasing. This study evaluates the effect of daily consumption of an antioxidant-rich juice (ARJ) on oxidative status, cardiovascular disease risk parameters, and untargeted plasma and urine metabolomes. Twenty-eight healthy young adults participated in an 8-week clinical trial by drinking 200 mL of ARJ (pomegranate and grape) daily. At the end of the study, the subjects showed a significant decrease (−29 %) in plasma lipid oxidation (malondialdehyde concentration), and a significant increase (+115 %) in plasma antioxidant capacity. Plasma and urine metabolomes were also significantly modified and some ions modified in urine were identified, including metabolites of polyphenols, ascorbic acid and biliary acids. No significant changes were observed in lipid profile, inflammation, blood pressure or glycaemia. These results show that incorporating antioxidant-rich beverages into common diets may improve oxidative status in healthy subjects.
- Published
- 2015
20. Obtainment and characterization of a potential functional ingredient from olive
- Author
-
Pérez-Jiménez, Jara, Díaz Rubio, M. Elena, Saura Calixto, Fulgencio D., Pérez-Jiménez, Jara, Díaz Rubio, M. Elena, and Saura Calixto, Fulgencio D.
- Abstract
Current olive oil production methods generate huge amounts of polluting waste, containing most of the health-related compounds in olive. Here, a new product is obtained from olive after pitting, drying and oil extraction, without generating waste. Its characterization showed the presence, within a single matrix, of more than 90% of the polyphenols present in olive, including hydroyxtyrosols (commonly not transferred to olive oil), dietary fiber, oleic acid and polyalcohols. This product is a potential new functional ingredient, consumption of which may lead to additive and/or synergic activities among its constituents; some of which already have approved health claims. Additionally, the olive oil obtained exhibits profiles of fatty acids and phenolic compounds similar to those of commercial olive oil. The procurement of this potential functional ingredient may represent a new approach to the revalorization of olive that additionally decreases waste.
- Published
- 2015
21. Procedimiento para la obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna
- Author
-
Saura Calixto, Fulgencio D. and Díaz Rubio, M. Elena
- Subjects
stomatognathic diseases ,stomatognathic system - Abstract
[EN] The invention relates to a method for obtaining olive oil and at least one multifunctional ingredient from olives. The method is characterised in that it comprises the following steps consisting in: (a) obtaining olive pulp, (b) dehydrating the olive pulp to produce a dehydrated olive pulp, (c) grinding the dehydrated olive pulp to produce a dry dehydrated olive powder, and (d) obtaining olive oil and at least one multifunctional ingredient from dry dehydrated olive powder. In addition, the invention relates to the resulting multifunctional ingredient and to the use thereof., [ES] La presente invención se refiere a un procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna, caracterizado por que comprende: (a) obtener pulpa de aceituna; (b) deshidratar la pulpa de aceituna, dando lugar a pulpa de aceituna deshidratada; (c) moler la pulpa de aceituna deshidratada, dando lugar a polvo seco de aceituna deshidratada; (d) obtener aceite de oliva y al menos un ingrediente multifuncional a partir de polvo seco de aceituna deshidratada, mediante una etapa de extracción con un disolvente orgánico, dando lugar a un sólido desengrasado que consiste en el ingrediente multifuncional y una fase líquida que comprende el aceite y el disolvente orgánico. Asimismo, es objeto de invención el ingrediente multifuncional obtenible a partir de dicho procedimiento y su uso., Consejo Superior de Investigaciones Científicas (España), A1 Solicitud de patente con informe sobre el estado de la técnica
- Published
- 2011
22. Procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna
- Author
-
Saura Calixto, Fulgencio D. and Díaz Rubio, M. Elena
- Abstract
La presente invención se refiere a un procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna, caracterizado porque comprende: (a) obtener pulpa de aceituna; (b) deshidratar la pulpa de aceituna, dando lugar a pulpa de aceituna deshidratada; (c) moler la pulpa de aceituna deshidratada, dando lugar a polvo seco de aceituna deshidratada; (d) obtener aceite de oliva y al menos un ingrediente multifuncional a partir de polvo seco de aceituna deshidratada, mediante una etapa de extracción con un disolvente orgánico, dando lugar a un sólido desengrasado que consiste en el ingrediente multifuncional y una fase líquida que comprende el aceite y el disolvente orgánico. Asimismo, es objeto de invención el ingrediente multifuncional obtenible a partir de dicho procedimiento y su uso., Consejo Superior de Investigaciones Científicas (España), B1 Patente sin examen previo
- Published
- 2011
23. Method for obtaining olive oil and at least one multifunctional ingredient from olives
- Author
-
Saura Calixto, Fulgencio D. and Díaz Rubio, M. Elena
- Abstract
[EN] The invention relates to a method for obtaining olive oil and at least one multifunctional ingredient from olives. The method is characterised in that it comprises the following steps consisting in: (a) obtaining olive pulp, (b) dehydrating the olive pulp to produce a dehydrated olive pulp, (c) grinding the dehydrated olive pulp to produce a dry dehydrated olive powder, and (d) obtaining olive oil and at least one multifunctional ingredient from dry dehydrated olive powder. In addition, the invention relates to the resulting multifunctional ingredient and to the use thereof. [ES] La presente invención se refiere a un procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna, caracterizado por que comprende: (a) obtener pulpa de aceituna; (b) deshidratar la pulpa de aceituna, dando lugar a pulpa de aceituna deshidratada; (c) moler la pulpa de aceituna deshidratada, dando lugar a polvo seco de aceituna deshidratada; (d) obtener aceite de oliva y al menos un ingrediente multifuncional a partir de polvo seco de aceituna deshidratada, mediante una etapa de extracción con un disolvente orgánico, dando lugar a un sólido desengrasado que consiste en el ingrediente multifuncional y una fase líquida que comprende el aceite y el disolvente orgánico. Asimismo, es objeto de invención el ingrediente multifuncional obtenible a partir de dicho procedimiento y su uso. Peer reviewed Consejo Superior de Investigaciones Científicas (España) A1 Solicitud de patente con informe sobre el estado de la técnica
- Published
- 2011
24. Obtainment and characterization of a potential functional ingredient from olive
- Author
-
Pérez-Jiménez, Jara, primary, Díaz-Rubio, M. Elena, additional, and Saura-Calixto, Fulgencio, additional
- Published
- 2015
- Full Text
- View/download PDF
25. Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1
- Author
-
Cuenca, F., Fernández, C., Devesa, M. J., López-Alonso, G., Mayol, J., Suárez, A., Ortega, L., Díaz-Rubio, M., and Ladero, J. M.
- Subjects
Hepatitis C virus ,Thyroid hormones ,Ribavirin ,Predictive factors ,Pegylated interferon - Abstract
Background and aims: more than half of patients with genotype 1 chronic hepatitis C (CHC) do not achieve a sustained viral response (SVR) to current antiviral therapy due to primary non-response, relapse or intolerance. Factors related to each of these unfavorable outcomes are different and the last two may be partially prevented. Our aim was to identify basal criteria to predict the risk of primary failure. Patients and methods: we included 251 consecutive patients (152 males) from a single centre, infected with HCV genotype 1 and not previously treated. SVR was achieved in 141 patients and primary failure in 110. Results: high vs. low viral load (> 400,000 IU/mL, OR = 6.17; 95% CI: 2.50-15.23), high serum GGT (> 60 IU/mL, OR = 4.25; 95% CI: 2.49-7.24), low serum cholesterol (< 178 mg/dL, OR = 2.93; 95% CI: 1.75-4.92) and older age (> 47 yrs., OR = 1.79; 95% CI: 1.08-2.96) were associated to the risk of primary failure in the lineal logistic regression analysis. From the 58 patients carrying all the first three negative criteria, 46 (79.3%) were primary non-responders. Conclusions: the negative basal profile identified in this study is based on easily available data and provides information about the risk of primary therapeutic failure, and may help to decide whether antiviral therapy should be offered to a single patient.
- Published
- 2010
26. Evidence for the formation of maillardized insoluble dietary fiber in bread: A specific kind of dietary fiber in thermally processed food
- Author
-
Pérez-Jiménez, Jara, Díaz Rubio, M. Elena, Morales, F. J., Saura Calixto, Fulgencio D., Pérez-Jiménez, Jara, Díaz Rubio, M. Elena, Morales, F. J., and Saura Calixto, Fulgencio D.
- Abstract
Bakery products are rich in insoluble dietary fiber (IDF), and Maillard reaction products (MRP), which are commonly studied as two independent constituents. The aim of this work was to elucidate whether IDF contains MRP as an intrinsic constituent, as well as to check the possible contribution of polyphenols to MRP in bread. It was found that MRP contribute to the increase in IDF from wheat flour to bread; indeed, 8% of furosine (a common indicator of MR) is associated with IDF. Also, ferulic acid and (-)-epicatechin got incorporated to MRP in a model system. This work provides evidence for the existence of a complex DF-protein-MRP-polyphenols, named maillardized IDF, in bakery products, a term applicable to other thermally processed food. Moreover, the present results strengthen the concept that MRP are formed not only from reducing sugars and amino acids, but also from phenolic compounds, including phenolic acids and flavonoids. © 2013 Elsevier Ltd.
- Published
- 2014
27. Regular Consumption of an Antioxidant-rich Juice Improves Oxidative Status and Causes Metabolome Changes in Healthy Adults
- Author
-
Díaz-Rubio, M. Elena, primary, Pérez-Jiménez, Jara, additional, Martínez-Bartolomé, Miguel Ángel, additional, Álvarez, Inmaculada, additional, and Saura-Calixto, Fulgencio, additional
- Published
- 2014
- Full Text
- View/download PDF
28. Tasas de aparición y desaparición de los síntomas de reflujo gastroesofágico en la población española y su impacto sobre la calidad de vida
- Author
-
Rey, E., Álvarez-Sánchez, A., Rodríguez-Artalejo, F., Moreno Elola-Olaso, C., Almansa, C., and Díaz-Rubio, M.
- Subjects
Quality of life ,Gastroesophageal reflux ,fungi - Abstract
Background: few studies have reported the onset and disappearance rates of gastroesophageal reflux symptoms (GERS) in the population. Aim: to assess the occurrence and disappearance rates of GERS in Spain, and their impact on health-related quality of life (HRQL). Participants and methods: participants were selected at random from the general population of Madrid in age and sex strata. They were interviewed at home twice, 6 months apart. Heartburn, acid regurgitation and consultation were assessed with the gastroesophageal reflux questionnaire, and HRQL with the SF-36. Results: 709 individuals were included, and 451 (63.6%) were re-interviewed 6 months later. Among the 325 individuals without GERS, 9 developed weekly symptoms (2.2% [95% CI: 0.8, 3.4%]); 2 (22%) consulted because of GERS. Among the 34 subjects reporting weekly GERS initially, 26 did not report them at 6-months. Onset of GERS was associated with worsening scores in the physical summary of SF-36 (delta = -6.6 [95% CI: -11.8, -1.42]), while disappearance with an improved score (delta = -3.0 [95% CI: 0.0, 5.9]). Conclusion: despite the lower prevalence of GERS in Spain, the occurrence rate is 2.2% in 6 months; however symptoms disappeared in more than half of subjects six months later. Developing GERS was associated with reduced HRQL, and their disappearance with improvement.
- Published
- 2009
29. Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C
- Author
-
Ladero, J. M., López-Alonso, G., Devesa, M. J., Cuenca, F., Ortega, L., Agreda, M., Suárez, A., Ropero, P., and Díaz-Rubio, M.
- Subjects
Ribavirin ,Ribavirina ,Ferritina sérica ,Hepatitis C ,Serum ferritin ,Pegylated interferon ,Interferón pegilado - Abstract
Background: hyperferritinemia is often found in patients with chronic hepatitis C (CHC) and is predictive of poorer response to antiviral therapy. Objective: to investigate changes in ferritinemia during and after antiviral therapy. Patients and methods: serum ferritin levels were measured in 262 CHC patients (163 males, mean age 48.5 years ± 10.1) before and during antiviral therapy, and six months post-treatment in all 154 patients whit undetectable serum HCV-RNA after therapy completion. Results: baseline serum ferritin was higher in patients with primary therapeutic failure than in those reaching sustained viral response (330 ± 291 ng/mL vs. 211 ± 192 ng/mL, p = 0.002). Serum ferritin transiently increased during therapy from baseline (257 ± 242 ng/mL vs. 875 ± 630 ng/mL, p < 0.001). Six months after finishing therapy, serum ferritin decreased under baseline values both in sustained responders (117 ± 102 ng/mL vs. 211± 192 ng/mL, p < 0.001) and, to a lesser extent, in relapsers (217 ± 174 ng/mL vs. 257 ± 221 ng/mL, p = 0.047). Conclusions: baseline serum ferritin may predict response to antiviral treatment in chronic hepatitis C. Combined antiviral therapy induces a marked increase in serum ferritin that falls below baseline values after sustained viral response, suggesting that the cause of hyperferritinemia in many patients is HCV infection itself rather than iron overload. Antecedentes: la hiperferritinemia es frecuente en los enfermos con hepatitis crónica C (HCC) y reduce las probabilidades de respuesta al tratamiento antiviral. Objetivo: investigar las variaciones de la ferritina sérica durante y después del tratamiento y su relación con la respuesta al mismo. Pacientes y métodos: la ferritina sérica se ha medido en 262 enfermos con HCC (163 hombres, edad media 48,5 años ± 10,1) antes y durante el tratamiento antiviral, y a los 6 meses de finalizado en los 154 enfermos con viremia indetectable al final del tratamiento. Resultados: la ferritina sérica basal era más alta en enfermos con fracaso terapéutico primario que en los que consiguieron respuesta viral sostenida (RVS) (330 ± 291 ng/ml vs. 211 ± 192 ng/ml, p = 0,002). La ferritina sérica aumentó transitoriamente durante el tratamiento (257 ± 242 ng/ml vs. 875 ± 630 ng/ml, p < 0,001). La ferritina sérica descendió a valores inferiores a los basales seis meses después de finalizado el tratamiento en los pacientes con RVS (117 ± 102 ng/ml vs. 211± 192 ng/ml, p < 0,001) y, en menor grado, en los que sufrieron recidiva viral (217 ± 174 ng/ml vs. 257 ± 221 ng/m, p = 0,047). Conclusiones: una ferritina sérica basal elevada se asocia con mayor riesgo de fracaso terapéutico en la HCC. El tratamiento antiviral induce un marcado incremento de la ferritina sérica que vuelve a valores por debajo de los basales en los enfermos que obtienen R vs. Esto sugiere que la causa de hiperferritinemia en la mayoría de los enfermos es la propia infección por VHC y no la sobrecarga de hierro.
- Published
- 2009
30. Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto
- Author
-
López Palacios, N., Mendoza, J. L., Taxonera, C., Lana, R., Fuentes Ferrer, M., and Díaz-Rubio, M.
- Subjects
Crohn's disease ,Adalimumab ,Enfermedad de Crohn ,Maintenance therapy ,Tratamiento de mantenimiento ,Enfermedad fistulosa perianal ,Perianal fistulizing disease ,Luminal - Abstract
Introducción: el adalimumab ha demostrado, en ensayos clínicos controlados con placebo y en estudios no controlados, ser efectivo en la EC luminal y fistulosa perianal. Objetivo: evaluar la eficacia y seguridad del adalimumab como tratamiento de inducción y mantenimiento en la EC. Metodología: se incluyeron 22 pacientes con EC tratados con adalimumab (16 por enfermedad luminal y 6 por enfermedad fistulosa perianal activa). Veintiún pacientes habían recibido previamente IFX. Se realizó tratamiento de inducción con 160 mg s.c. en la semana 0 y 80 mg s.c. a las 2 semanas. Los respondedores recibieron 40 mg s.c. cada 14 días como tratamiento de mantenimiento. Se valoró la respuesta a las 4 semanas de la dosis inicial, y se clasificó la respuesta como remisión, respuesta parcial o ausencia de respuesta. Resultados: tras la inducción, el 25% de los pacientes con enfermedad luminal tuvieron remisión completa y el 56,3% respuesta parcial. La respuesta clínica se mantuvo al año en el 71,6% de los pacientes, a los 18 meses en el 53,7% y a los 48 meses en el 35,8%. No se objetivaron diferencias en la respuesta entre pacientes que presentaron reacciones de hipersensibilidad o pérdida de respuesta a IFX. Todos los pacientes con enfermedad fistulosa perianal (n = 6) habían recibido previamente tratamiento con IFX. Tras la inducción un 16,7% entran en remisión y un 66,7% presentan respuesta parcial. Todos los pacientes mantienen remisión o respuesta en el tiempo con una mediana de seguimiento de 15 meses. Conclusiones: el adalimumab es un tratamiento eficaz y seguro en la inducción y mantenimiento de la respuesta en la EC luminal y fistulosa perianal. Estos resultados confirman que los hallazgos obtenidos en los ensayos clínicos controlados son reproducibles en la práctica clínica diaria. Background: adalimumab has been shown in placebo-controlled clinical trials and uncontrolled studies to be effective in luminal and perianal fistulizing CD. Objective: to evaluate the efficacy and safety of adalimumab for induction and maintenance therapy in CD. Methods: twenty-two patients with CD treated with adalimumab (16 for luminal disease and 6 for active perianal fistulizing disease) were included. Twenty-one patients had previously received IFX. All patients received induction therapy with 160 mg s.c. at week 0, and 80 mg s.c. at week 2. Responders received maintenance therapy with 40 mg s.c. every 14 days. Response was assessed at 4 weeks after the initial dose, and classified as remission, partial response, or non-response. Results: after induction, 25% of patients with luminal disease had a complete remission, and 56.3% had a partial response. Clinical response was maintained in 71.6% of patients at 1 year, in 53.7% at 18 months, and in 35.8% at 48 months. No differences in response were observed between patients with hypersensitivity reactions or loss of response to IFX. All patients with perianal fistulizing disease (n = 6) had been previously treated with IFX. After induction 16.7% entered remission, and 66.7% had a partial response. All patients maintained remission or response over time, with a median follow-up of 15 months. Conclusions: adalimumab is an effective and safe treatment for the induction and maintenance of response in luminal and perianal fistulizing CD. These results confirm that the findings obtained in controlled clinical trials are reproducible in clinical practice.
- Published
- 2008
31. Resultados del tratamiento de la hepatitis crónica por VHC genotipo 4: Un análisis comparativo con el genotipo 1
- Author
-
López-Alonso, G., Ágreda, M., Devesa, M. J., Cuenca, F., Suárez, A., Ortega, L., Díaz-Rubio, M., and Ladero, J. M.
- Subjects
Ribavirin ,Ribavirina ,Chronic hepatitis C ,Hepatitis C virus genotype 4 ,Hepatitis crónica C ,Virus de la hepatitis C genotipo 4 ,Pegylated interferon ,Interferón pegilado - Abstract
Antecedentes y objetivos: casi todos los datos sobre la eficacia del tratamiento antiviral combinado en la infección por el virus de la hepatitis C (VHC) genotipo 4, que es poco frecuente en España, se han obtenido en países del Oriente Próximo. Aportamos nuestra experiencia en pacientes tratados en España con criterios homogéneos. Pacientes y métodos: en el periodo 2001-2007 hemos tratado a 30 enfermos con hepatitis crónica por VHC genotipo 4 (20 varones) con interferón pegilado α-2b (26 casos) o α-2a (4 casos) y ribavirina en dosis ajustada al peso. En todos los casos se conoce el resultado del tratamiento y se dispone de bioquímica y datos virológicos basales, y en 24 de biopsia hepática. Hemos comparado estos resultados con los obtenidos en 355 pacientes infectados por VHC genotipo 1. Resultados: diez pacientes (33,3%) obtuvieron respuesta viral sostenida (RVS: ARN del VHC negativo en sangre a los 6 meses de finalizado el tratamiento), 12 no respondieron (fracaso viral primario), 4 recidivaron y 4 abandonaron por intolerancia. Estos resultados son muy similares a los obtenidos en el grupo de genotipo 1 (RVS: 35,1%). Conclusión: el genotipo 4 del VHC debe considerarse como tan "difícil de tratar" como el genotipo 1. La mayor eficacia del tratamiento en otras zonas geográficas (Oriente Próximo) pueden deberse a la diferente distribución de los subtipos virales existentes. Introduction: nearly all the data on the efficacy of combined antiviral therapy on chronic hepatitis C genotype 4 have been obtained in countries of Middle East. Genotype 4 is quite unusual in Spain. We report our experience in a group of Spanish patients treated with homogeneous criteria. Patients and methods: between 2001 and 2007 we have treated 30 patients with chronic hepatitis C genotype 4 (20 males) with pegylated Interferon a-2b (26 cases) or a-2a (4 cases) combined with ribavirin at a weight-adjusted dose. Results of therapy are known in all patients and liver biopsy is available in 24 cases. Results: ten patients (33.3%) obtained sustained viral response (SVR: HCV-RNA undetectable in blood 6 months after the end of therapy), 12 were primary non-responders, 4 relapsed after reaching undetectable HCV-RNA at the end of therapy and 4 interrupted the treatment due to severe adverse events. These results are very close to those obtained in 355 patients infected with HCV genotype 1. Conclusion: HCV genotype 4 should be considered as "difficult to treat". The better results of therapy in other geographical areas (Middle East) may be due to a different distribution of the subtypes of HCV genotype 4.
- Published
- 2008
32. Developing functional seafood products
- Author
-
Careche, Mercedes, Saura Calixto, Fulgencio D., Díaz Rubio, M. Elena, Borderías, A. Javier, Sánchez Alonso, Isabel, Carmona, Pedro, Sánchez González, I., and Larsen E.H.
- Subjects
education - Published
- 2008
33. Prevalencia de la infección por Helicobacter pylori en población sana en la Comunidad de Madrid
- Author
-
Sánchez Ceballos, F., Taxonera Samsó, C., García Alonso, M., Alba López, C., Sainz de los Terreros Soler, L., and Díaz-Rubio, M.
- Subjects
Helicobacter pylori ,Test del aliento ,Epidemiology ,Prevalence ,Epidemiología ,Prevalencia ,Breath test - Abstract
Objetivo: conocer la prevalencia de la infección por Helicobacter pylori en población sana en la Comunidad de Madrid. Material y métodos: estudio transversal descriptivo en el que se realiza el diagnóstico de la infección por Helicobacter pylori mediante la prueba del test del aliento con 13C-urea. Resultados: se estudian un total de 618 sujetos. De estos, 481 son considerados evaluables con una prevalencia de infección por Helicobacter pylori del 60,3%. En esta cohorte el 36,4% eran varones y el 63,6% mujeres con una prevalencia del 60,6 y 60,1% respectivamente sin diferencias significativas. La mediana de edad de los pacientes evaluados fue de 37,5 años (rango 4-82) estableciéndose que existe una relación lineal con significación estadística entre la infección por Helicobacter pylori y la edad (χ² lineal = 33,31; p < 0,001): a mayor edad mayor probabilidad de infección. La prevalencia aumenta con la edad siendo máxima entre los 60 y 69 años (83,3% infectados). En 169 sujetos (35,1%) se conoce el nivel de estudios sin que exista relación entre este y la infección por Helicobacter pylori. Conclusión: el estudio muestra que la prevalencia de la infección por Helicobacter pylori en población sana en Madrid es elevada (60,3%), y aumenta progresivamente a lo largo de la vida para alcanzar un pico máximo en la 6ª década. No se encuentran diferencias en la muestra en función del sexo ni del nivel de estudios. Objective: to determine the prevalence of Helicobacter pylori infection in the healthy population of Madrid Autonomous Community (AC). Material and methods: a descriptive, cross-sectional study where Helicobacter pylori infection is diagnosed by means of the 13C-urea breath test. Results: a total of 618 subjects were studied. Among these, 481 were considered evaluable with a prevalence of Helicobacter pylori infection of 60.3%. In this cohort 36.4% were men and 63.6% were women, with a prevalence of 60.6 and 60.1%, respectively, and no relevant differences between both subgroups. The median age of patients was 37.5 years (range 4-82), and a statistically significant linear relationship between Helicobacter pylori infection and age (linear χ² =33.31; p < 0.001) was established -chances of infection increase with age. Prevalence increases with age and peaks at 60 to 69 years (83.3% infected). For 169 subjects (35.1%) education level was unknown, and no relationship between this level and Helicobacter pylori infection was found. Conclusions: the study shows that the prevalence of Helicobacter pylori infection in the healthy population of Madrid AC is high (60.3%), progressively increases with age, and peaks in people in their sixties. The sample showed no differences regarding sex or education level.
- Published
- 2007
34. Opinión de los médicos españoles sobre el síndrome de intestino irritable: Resultados de un estudio utilizando el método Delphi
- Author
-
Almansa, C., Rey, E., Bolaños, E., Palma, M., Álvarez Sánchez, A., and Díaz-Rubio, M.
- Subjects
Irritable bowel syndrome ,Estudio Delphi ,Síndrome del intestino irritable ,Delphi survey - Abstract
Introducción: el síndrome del intestino irritable (SII) es una patología controvertida, donde ante la escasez de evidencia científica las recomendaciones sobre su manejo clínico y su definición vienen determinadas por métodos de consenso de expertos. Objetivo: obtener la opinión de los médicos de nuestro país implicados en el manejo de pacientes con SII y conocer los puntos de acuerdo en las principales cuestiones clínicas que plantea. Material y métodos: se realizó un estudio Delphi a nivel nacional mediante dos envíos a 100 médicos de atención primaria y gastroenterólogos. El cuestionario incluía preguntas sobre el concepto, diagnóstico y tratamiento del SII, evaluando el grado de acuerdo entre los participantes. Resultados: el 55% de los encuestados completó los dos envíos. Se obtuvo acuerdo respecto a los síntomas que caracterizan al SII y los de alarma. No existió una actitud clara ante el paciente sin síntomas de alarma, pero sí acuerdo respecto a la realización de colonoscopia en su presencia. Se señaló la necesidad de realizar estudios complementarios en mayores de 40 años. En el tratamiento no encontramos una actitud uniforme, aunque parece existir una orientación diferente según el síntoma predominante. Conclusiones: los médicos participantes en el estudio demuestran a través de sus respuestas un buen conocimiento conceptual del SII, si bien las discrepancias observadas en las cuestiones sobre diagnóstico y tratamiento demuestran la complejidad y falta de uniformidad que existe en el manejo diario de este síndrome. Introduction: lack of evidence in most clinical situations regarding irritable bowel syndrome (IBS) enhances the importance of an expert's opinion, which will guide management and even the concept underlying the disease. Objective: to delve into the knowledge and degree of agreement on main clinical skills for this syndrome among physicians involved in its management. Material and method: two rounds of a Delphi survey were conducted on 100 physicians: general practitioners (GPs) and gastroenterologists. The questionnaire evaluated agreement among participants in some aspects regarding the definition, diagnosis, and treatment of IBS. Results: fifty-five percent of participants completed the two-round survey. Agreement was achieved regarding the definition of typical symptoms and red flags characterizing IBS. Although there was no consensus regarding the appropriate management of patients without alarm symptoms, the performance of a colonoscopy on any patient presenting red flags was suggested. Patients were thought to require a wider examination when older than 40. A well defined line of IBS treatment was not found, albeit most physicians tended to choose it depending on the main complaint. Conclusion: interviewed physicians showed adequate theoretical knowledge of IBS, but lack of uniformity on diagnosis and treatment approach reflects the controversial day-by-day management of this syndrome.
- Published
- 2007
35. Diagnostic yield and safety of capsule endoscopy
- Author
-
Matas, J. L., Asteinza, M., Loscos, J. M., Fernández, S., Ramírez-Armengol, J. A., and Díaz-Rubio, M.
- Subjects
Obscure digestive bleeding ,Crohn's disease ,Iron deficiency anemia ,Anemia ferropénica ,Cápsula endoscópica ,Occult gastrointestinal bleeding ,Hemorragia digestiva crónica ,Capsule endoscopy ,Enfermedad de Crohn ,Hemorragia gastrointestinal de origen oscuro - Abstract
Introduction: the capsule endoscopy (CE), from his approval, has become a first line diagnostic procedure for the study of the small bowel disease. The aim of this study is to report our experience since the implantation of this technique in our hospital. Material and methods: retrospective review of the CE undertaken in Department of Endoscopy. There was gathered in every case the age, sex, motive of consultation, previous diagnostic procedures, capsule endoscopy findings and complication of the technique. One took to end a descriptive and analytical analysis. Results: there was achieved a total of 416 explorations in 388 patients. The obscure gastrointestinal bleeding was the most frequent indication (83.30%) followed by suspected Crohn's disease (7.5%). Angiodisplasia was the endoscopic lesion more frequently detected (42.2%), especially, in patients with digestive bleeding of obscure origin (OR 3.13 p < 0.001), followed by the flebectasia (10.6%) and the ulcer suspicious of Crohn’s disease (9.9%). The global diagnostic yield as for the detection of injuries was 77.34% with a case of "not defecation of the capsule' and therefore need of laparotomy. Conclusions: the capsule endoscopy is a technique consolidated and as his potential is known, his indications are extended. The obscure gastrointestinal bleeding is the most frequent indication and the angiodisplasia the most identified injury. Once known his diagnostic yield, larger studies are needed that assess the influence of capsule endoscopy on clinical outcoumes. Introducción: la cápsula endoscópica desde su aprobación se ha convertido en un procedimiento diagnóstico de primera línea para el estudio del intestino delgado. El objetivo del estudio es exponer la experiencia desde la implantación de esta técnica en nuestro hospital. Material y métodos: se hizo una revisión retrospectiva de los estudios realizados en el Servicio de Endoscopia. Se recogió en cada caso la edad, sexo, motivo de consulta, procedimientos diagnósticos previos, diagnósticos endoscópicos e incidencias inherentes a la técnica y se llevó a cabo un análisis descriptivo y analítico. Resultados: se realizaron un total de 416 exploraciones en 388 pacientes. La hemorragia digestiva de origen oscuro fue la indicación más frecuente (83,30%) seguida de la sospecha de enfermedad de Crohn (7,5%). La angiodisplasia fue la lesión endoscópica más detectada (42,2%) cuando se analizó la hemorragia digestiva oscura (OR 3.13 p < 0,001) seguida de la flebectasia (10,6%) y las úlceras sugerentes de enfermedad de Crohn (9,9%). La rentabilidad global en cuanto a la detección de lesiones fue del 77,34% con un caso de "no defecación de la cápsula' y por lo tanto de necesidad de laparotomía. Conclusiones: la cápsula endoscópica es una técnica consolidada y a medida que se conoce su potencial, se van ampliando sus indicaciones. La hemorragia digestiva de origen oscuro es la indicación más frecuente y la angiodisplasia la lesión más identificada. Una vez conocida su eficacia diagnóstica se hace necesario determinar mediante estudios a gran escala y con metodología precisa la rentabilidad clínica de la misma.
- Published
- 2006
36. Síndrome del nevus gomoso azul (blue rubber bleb nevus) diagnosticado por cápsula endoscópica
- Author
-
Matas, J. L., Asteinza, M., Loscos, J. M., Fernández, S., Ramírez-Armengol, J. A., and Díaz-Rubio, M.
- Published
- 2006
37. Impact of gastroesophageal reflux symptoms on health resource usage and work absenteeism in Spain
- Author
-
Rey, E., Moreno Elola-Olaso, C., Rodríguez Artalejo, F., and Díaz-Rubio, M.
- Subjects
Gastroesophageal reflux ,Epidemiology ,Absenteeism ,Pyrosis ,Utilization of resourses - Abstract
Objectives: to estimate the impact of gastroesophageal reflux (GER) symptoms on the utilization of healthcare services and work absenteeism in Spain. Methods: a cross-sectional study on 2,500 subjects representative of the Spanish population from 40 to 79 years of age. Data were collected via a telephone interview in January 2002 using Locke's questionnaire after its cross-cultural adaptation and validation for telephone use in Spain. Results: GER is responsible for 296.8 doctor consultations (95% CI: 245.3-348.7) per 1,000 inhabitants per year, for 24 esophagogastrointestinal radiographic studies per 1,000 inhabitants per year (95% CI: 18-30), for 32.4 (95% CI: 25.5-39.3) high digestive endoscopies per 1,000 inhabitants per year, and for the loss of 201 (95% CI: 0-411.1) working days per 1,000 employed inhabitants with GER per year. In relation to medication intake, GER resulted in 4,092 (95% CI: 3,300-5,133) treatment days with H2 antagonists per 1,000 inhabitants per year, 9,030 (95% CI: 7,846-10,332) treatment days with proton pump inhibitors per 1,000 inhabitants per year, and 1,082 (95% CI: 519-1,549) treatment days with prokinetics per 1,000 inhabitants per year. Conclusions: GER has a large impact on the utilization of healthcare resources and work absenteeism in Spain, in contrast to the widespread belief that it is an illness of little importance.
- Published
- 2006
38. Polymorphisms in the interleukin-10 gene and relation to phenotype in patients with ulcerative colitis
- Author
-
Mendoza, J. L., Urcelay, E., Lana, R., Martínez, A., Taxonera, C., Concha, E. G. de la, and Díaz-Rubio, M.
- Subjects
Interleukin-10 gene ,Phenotype ,Ulcerative colitis ,Colitis ulcerosa ,Enfermedad inflamatoria intestinal ,Gen de la interleuquina-10 ,Fenotipo ,Inflammatory bowel disease - Abstract
Background and objectives: interleukin-10 (IL-10) has a key role in regulating mucosal inflammation in inflammatory bowel disease. In our population of Spanish ulcerative colitis (UC) patients, we have previously demostrated that two polymorphisms (IL-10.G14 microsatellite allele and homozygous for the -1082G alelle (guanine at position -1082)) in the IL-10 gene were susceptibility markers for disease. No data exist regarding the relationship of these IL-10 polymorphims with phenotypic subpopulations in UC. Therefore, this study sought to examine the contribution of IL-10 polymorphims to phenotypical variability in UC. Material and methods: a cohort of 215 Spanish unrelated patients with UC recruited in a single center was studied. All patients were rigorously phenotyped and followed for at least 3 years (mean time: 11.8 years). The clinical phenotype was established before genotyping. Genotyping was performed using polymerase chain reaction (PCR) assays. Results: patiens with UC included 129 (60%) men and 89 (40%) women. Mean age at diagnosis was 38 years, with a range of 8-83. Disease extent included 127 (59.1%) left-side patients and 88 (40.9%) extensive patients. Neither UC phenotype variable was associated with the presence of susceptibility polymorphims (10G14 microsatellite and -1082G alelle). Conclusions: in Madrid's Spanish population of UC patients, the carrying of the ILG14 microsatellite or -1082G polymorphism in the IL-10 gene was not associated with phenotype of disease. Introducción y objetivo: el gen de la interleuquina 10 (IL-10) tiene un papel clave en la regulación de la inflamación intestinal en la enfermedad inflamatoria intestinal. Recientemente hemos descubierto que dos polimorfismos del gen de la IL-10, el microsatélite IL-10.G14 y ser homocigoto -1082G (guanina en la posición 1082 del gen promotor de la IL-10) son marcadores de susceptibilidad para padecer colitis ulcerosa (CU). No existen datos que demuestren si estos polimorfismos de la IL-10 se correlacionan con las características fenotípicas de la CU. En este trabajo se estudia la relación entre estos polimorfismos del gen de la IL-10 y las diferentes características fenotípicas de la CU. Material y métodos: se estudió una cohorte de 215 pacientes españoles no emparentados que son atendidos habitualmente en la consulta de un único centro hospitalario. Todos los pacientes fueron rigurosamente fenotipados y seguidos clínicamente durante al menos 3 años (tiempo medio de seguimiento 11,8 años). El fenotipaje se realizó antes de conocer el genotipo de los pacientes. El genotipaje se realizó según las técnicas habituales de reacción en cadena de la polimerasa. Resultados: se incluyeron 129 (60%) hombres y 89 (40%) mujeres. La edad media en el momento del diagnóstico fue de 38 años, rango (8-83). La extensión de la CU fue colitis izquierda en 127 (59,1%) pacientes y extensa en 88 (40,9%). Ninguna de la svariables fenotípicas estudiadas se asoció con la presencia o ausencia de los polimorfismos (microsatélite IL10G14 y homocigoto para el alelo -1082G) relacionados con la susceptibilidad a sufrir CU. Conclusiones: en la población española del área de Madrid, los pacientes con CU que son portadores del microsatélite IL10G14 y/o homocigotos -1082G del gen promotor de la IL-10 no se correlacionan con ninguna característica fenotípica de la enfermedad.
- Published
- 2006
39. Dietary fiber in wine
- Author
-
Díaz Rubio, M. Elena and Saura Calixto, Fulgencio D.
- Subjects
digestive, oral, and skin physiology ,food and beverages - Abstract
Indigestible polysaccharides are major constituents of dietary fiber. Polysaccharides in wine are usually studied in relation to sensory properties but a nutritional approach is also appropriate for this wine fraction. Grape pomace is rich in dietary fiber, and a significant amount of this fiber may pass into wine during the winemaking process; however, food composition tables report zero dietary fiber content for wines. The objective of this work was to ascertain whether dietary fiber is a common constituent of wine. Soluble dietary fiber was determined in several red and white wines from different Spanish regions by using a newly developed four-step analytical method: concentration of wine, enzymatic treatment, dialysis, and dietary fiber determination. Significant amounts of soluble dietary fiber were found in wine; dietary fiber content was higher in red wine (0.94 to 1.37 g/L) than in white wine (0.19 to 0.39 g/L). Copyright © 2006 by the American Society for Enology and Viticulture. All rights reserved.
- Published
- 2006
40. Divertículo de Zenker: diagnóstico mediante radiografía simple
- Author
-
Lana, R., Mendoza, J. L., Lérida, A. I., Rodríguez-Agulló, J. L., and Díaz-Rubio, M.
- Published
- 2005
41. Has the identification of rectal hypersensitivity any implication in the clinical outcome of irritable bowel syndrome?
- Author
-
Izquierdo, S., Rey, E., García Alonso, M., Almansa, C., and Díaz-Rubio, M.
- Subjects
Irritable bowel syndrome ,Sensitivity ,Sensibilidad ,Síndrome intestino irritable ,Use of health resources ,Consumo de recursos sanitarios - Abstract
Background: sixty percent of patients with irritable bowel disease (IBS) are hypersensitive to rectal distension. It is uncertain to what extend the identification of this abnormality has an impact in the clinical outcome. Objective: to evaluate if rectal hypersensitivity is associated with a different clinical outcome, prognosis and use of medical resources. Material and methods: patients with IBS (Rome II criteria) who underwent a rectal distension study at least one year before were eligible if they have not been included in any research protocol since then. We reviewed how many times in the last year they came to emergency room, underwent an endoscopy, and consulted a gastroenterologist or other medical physician for any reason. Also, a telephone interview was done by a gastroenterology fellow using a structured questionnaire to evaluate the frequency and severity of their symptoms in the last year and last month. Results: a total of 52 patients were eligible and 38 were included. Forteen were not included because inability to made a phone contact or did not consent to phone interview. Twenty six patients were hypersensitive and 12 normosensitive. Both groups had similar symptoms (frequency and severity) but hypersensitive patients visited less to the gastroenterologist (1.2 ± 0.2 vs. 2.9 ± 0.6 times yearly, p < 0.01). Conclusion: identification of rectal hypersensitivity to distension is associated to less consultation to gastroenterologist, although severity and frequency of symptoms are not modified. Finding of an objective explanation of the symptoms seems to help patients to understand their disease, leading to a decrease in resources' use. Introducción: el 60% de los pacientes con SII tienen hipersensibilidad a la distensión rectal. Se desconoce si la identificación de esta alteración puede modificar su evolución. Objetivo: evaluar si la hipersensibilidad a la distensión rectal se asocia con un diferente pronóstico respecto a la presentación de síntomas y la utilización de recursos sanitarios en pacientes con SII. Material y métodos: se incluyeron pacientes con SII según criterios de Roma II, que habían sido sometidos a un estudio de distensión rectal. Se recogieron datos de los registros informáticos sobre asistencia a consultas especializadas, realización de endoscopias, asistencia a urgencias e ingresos hospitalarios. Además, se realizó entrevista telefónica en la que se interrogó acerca de la existencia de síntomas a lo largo del último año y último mes (características, duración y severidad). Resultados: se evaluaron 38 pacientes, 26 con hipersensibilidad en el estudio de distensión basal y 12 normosensibles. En el momento de la recogida de datos (registro informático y entrevista telefónica) el seguimiento medio era de 2,39 años después del estudio de distensión. Los sujetos hipersensibles presentaron una clínica similar a aquellos normosensibles. Se registró una menor tasa de frecuentación anual en las consultas de Aparato Digestivo (1,2 ± 0,2 vs. 2,9 ± 0,6, p < 0,01) por parte de los pacientes hipersensibles sin existir diferencias en el resto de variables estudiadas. Conclusión: la identificación de hipersensibilidad visceral en pacientes con SII conlleva una notable reducción de las consultas al gastroenterólogo, sin que esto pueda explicarse por la mejoría de los síntomas, ni por una menor tendencia a realizar otras consultas médicas.
- Published
- 2005
42. Diagnostic and treatment recommendations on perianal Crohn's disease
- Author
-
Mendoza, J. L., Taxonera, C., Lana, R., Alba, C., García-Paredes, J., and Díaz-Rubio, M.
- Subjects
Treatment ,Crohn's disease ,Perianal disease ,Diagnóstico ,Tratamiento ,Diagnostic ,Enfermedad de Crohn ,Enfermedad perianal - Abstract
Treatment of perianal fistulas in Crohn's disease should be defined on an individual basis. A combined medical and surgical approach is the optimal treatment. Adequate management of perianal fistula disease is based on the presence or absence of active proctitis, anatomic location, and fistula type. Furthermore, the presence of perianal abscesses must be ruled out. This evaluation includes digital rectal examination, endoscopy, and examination under anesthesia combined with pelvic magnetic resonance imaging or anorectal endoscopy ultrasonography findings. El tratamiento de la enfermedad fistulosa perianal (EFPA) en la enfermedad de Crohn (EC) debe de ser individualizado y combinar procedimientos médicos y quirúrgicos. Los aspectos clave para un adecuado manejo de la EFPA son determinar la existencia o no de afectación rectal, las características anatómicas y tipo de fístulas, y descartar la existencia de abscesos perianales. Para lograrlo es necesaria una aproximación diagnóstica que incluya inspección y tacto rectal, endoscopia y exploración bajo anestesia combinado con resonancia magnética pélvica o ecografía anal.
- Published
- 2005
43. Chest pain of esophageal origin
- Author
-
Díaz-Rubio, M.
- Published
- 2004
44. Hereditary hyperferritinemia-cataract syndrome: Study of a new family in Spain
- Author
-
Ladero, J. M., Balas, A., García-Sánchez, F., Vicario, J. L., and Díaz-Rubio, M.
- Subjects
Cataratatas ,Cadenas L de ferritina ,Hiperferritinemia ,Hyperferritinemia ,Iron responsive element ,Proteínas reguladoras del hierro ,Ferritin L chain ,Cataract - Abstract
The hyperferritinemia-cataract syndrome, inherited as a Mendelian dominant trait, is due to mutations in the 5’ non-coding region of the ferritin light chain gene that modifies the shape of the IRE (iron responsive element) region, which loses its normal function of regulating the synthesis of ferritin light chains. Excess of light chains results in complexes that accumulate into the lens giving rise to early cataracts. We present a Spanish family with seven affected members through three generations. A genetic study reveals a substitution of a single base (C?T) at position 33 in the IRE sequence in the index case and in one affected brother, whereas a non-affected sister shows the normal sequence. The hyperferritinemia-cataract syndrome was identified in 1995 and is still poorly understood. Clinicians should suspect it when treating any subject with early cataracts, even more if they are familial, or in patients with very high levels of ferritinemia without evidence of iron overload. There are no known consequences of the syndrome other than cataracts, and its proper diagnosis carries a favorable prognosis and eliminates the risk of unnecessary phlebotomies. El síndrome de hiperferritinemia y cataratas es un trastorno autosómico dominante debido a mutaciones en la región 5’ no codificante del gen de la cadena ligera de ferritina, localizado en 19q.3-q13,4. Como consecuencia se altera la morfología de la region IRE (iron responsive element) que pierde su capacidad normal de regular la síntesis de cadenas ligeras de ferritina, las cuales se sintetizan en exceso y forman complejos que se acumulan en el cristalino, dando lugar a cataratas precoces. Se presenta una familia española con 7 miembros afectados en tres generaciones. El estudio genético pone de manifiesto un cambio de una sola base C?T en posición 33 del IRE en el caso index y un hermano, mientras que otra hermana no afecta del síndrome no mostraba mutaciones. Este síndrome se identificó en 1995 y aún es poco conocido. La sospecha clínica debe surgir ante sujetos con cataratas precoces, especialmente si son de tipo familiar, o en personas con cifras elevadas de ferritina sin causa aparente y sin signos de sobrecarga de hierro. El trastorno no parece tener otras consecuencias que las cataratas y su identificación permite establecer un pronóstico favorable y evitar sangrías terapéuticas innecesarias.
- Published
- 2004
45. Experience with granulocytapheresis in Crohn's disease
- Author
-
Cuenca, F., García-Paredes, J., Mendoza, J. L., Cruz, D. M., Herrero, A., and Díaz-Rubio, M.
- Subjects
Crohn's disease ,Ulcerative colitis ,Colitis ulcerosa ,Enfermedad inflamatoria intestinal ,Granulocitoaféresis ,Granulocyte apheresis ,Leukocyte apheresis ,Enfermedad de Crohn ,Leucitoaféresis ,Inflammatory bowel disease - Abstract
Objective: to describe our experience with granulocyte apheresis to induce remission in patients with active Crohn's disease refractory to conventional treatment. We summarize the results previously obtained with this technique. Conclusions: granulocyte apheresis is a safe and well tolerated therapeutic modality that can be a valid therapeutic alternative in the induction of remission in inflammatory bowel disease, although controlled clinical trials must be conducted to define long-term efficacy, as well as to establish “optimal patient” selection, re-treatment interval, and number of sessions. Objetivo: describir nuestra experiencia con la granulocitoaféresis para inducir la remisión en pacientes con enfermedad de Crohn activa refractarios al tratamiento convencional. Realizamos un resumen de los resultados previos obtenidos con esta técnica. Conclusiones: la granulocitoaféresis es una modalidad terapéutica segura y bien tolerada que puede ser una alternativa terapéutica válida en la inducción de la remisión en la enfermedad inflamatoria intestinal, siendo necesaria la realización de ensayos clínicos controlados para poder definir su eficacia a largo plazo, la selección del "paciente óptimo", intervalos de retratamiento y número de sesiones.
- Published
- 2004
46. Optimización en el tratamiento de formas complicadas de la enfermedad inflamatoria intestinal: Enfermedad de Crohn fistulizante
- Author
-
Peñate, M., Cruz-Santamaría, M., Mendoza, J. L., Peña, A. S., Díaz-Rubio, M., and García-Paredes, J.
- Published
- 2003
47. Procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna
- Author
-
Saura Calixto, Fulgencio D., Díaz Rubio, M. Elena, Saura Calixto, Fulgencio D., and Díaz Rubio, M. Elena
- Abstract
La presente invención se refiere a un procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna, caracterizado porque comprende: (a) obtener pulpa de aceituna; (b) deshidratar la pulpa de aceituna, dando lugar a pulpa de aceituna deshidratada; (c) moler la pulpa de aceituna deshidratada, dando lugar a polvo seco de aceituna deshidratada; (d) obtener aceite de oliva y al menos un ingrediente multifuncional a partir de polvo seco de aceituna deshidratada, mediante una etapa de extracción con un disolvente orgánico, dando lugar a un sólido desengrasado que consiste en el ingrediente multifuncional y una fase líquida que comprende el aceite y el disolvente orgánico. Asimismo, es objeto de invención el ingrediente multifuncional obtenible a partir de dicho procedimiento y su uso.
- Published
- 2013
48. Non-extractable polyphenols, a major dietary antioxidant: Occurrence, metabolic fate and health effects
- Author
-
Pérez-Jiménez, Jara, Díaz Rubio, M. Elena, Saura Calixto, Fulgencio D., Pérez-Jiménez, Jara, Díaz Rubio, M. Elena, and Saura Calixto, Fulgencio D.
- Abstract
Current research on dietary antioxidants misses the so-called non-extractable polyphenols (NEPP), which are not significantly released from the food matrix either by mastication, acid pH in the stomach or action of digestive enzymes, reaching the colon nearly intact. NEPP, not detected by the usual analytical procedures, are made up of macromolecules and single phenolic compounds associated with macromolecules. Therefore, NEPP are not included in food and dietary intake data nor in bioavailability, intervention or observational studies. The present paper aims to provide an overview of dietary NEPP - nature, occurrence in diet, metabolic fate and possible health effects. NEPP are a relevant fraction of dietary polyphenols exerting their main biological action in the colon, where they are extensively fermented by the action of microbiota, giving place to absorbable metabolites. NEPP exhibit different potential health-related properties, in particular in relation to gastrointestinal health, such as increases in antioxidant and antiproliferative capacities, reduction of intestinal tumorigenesis and modification of gene expression, as observed in different animal models. Further research into NEPP may provide a better understanding of the health effects of dietary antioxidants. © The Authors 2013.
- Published
- 2013
49. Method for obtaining olive oil and at least one multifunctional ingredient from olives
- Author
-
Saura Calixto, Fulgencio D., Díaz Rubio, M. Elena, Saura Calixto, Fulgencio D., and Díaz Rubio, M. Elena
- Abstract
[EN] The invention relates to a method for obtaining olive oil and at least one multifunctional ingredient from olives. The method is characterised in that it comprises the following steps consisting in: (a) obtaining olive pulp, (b) dehydrating the olive pulp to produce a dehydrated olive pulp, (c) grinding the dehydrated olive pulp to produce a dry dehydrated olive powder, and (d) obtaining olive oil and at least one multifunctional ingredient from dry dehydrated olive powder. In addition, the invention relates to the resulting multifunctional ingredient and to the use thereof., [ES] La presente invención se refiere a un procedimiento de obtención de aceite de oliva y de al menos un ingrediente multifuncional a partir de aceituna, caracterizado por que comprende: (a) obtener pulpa de aceituna; (b) deshidratar la pulpa de aceituna, dando lugar a pulpa de aceituna deshidratada; (c) moler la pulpa de aceituna deshidratada, dando lugar a polvo seco de aceituna deshidratada; (d) obtener aceite de oliva y al menos un ingrediente multifuncional a partir de polvo seco de aceituna deshidratada, mediante una etapa de extracción con un disolvente orgánico, dando lugar a un sólido desengrasado que consiste en el ingrediente multifuncional y una fase líquida que comprende el aceite y el disolvente orgánico. Asimismo, es objeto de invención el ingrediente multifuncional obtenible a partir de dicho procedimiento y su uso.
- Published
- 2013
50. Disseminated cytomegalovirus infection in immunocompetent patients
- Author
-
Izquierdo Rubio, S., Taxonera Samsó, C., Ladero Quesada, J. M., Almansa Menchero, C., and Díaz-Rubio, M.
- Subjects
Alcoholismo ,Citomegalovirus ,virus diseases ,Infección ,Cytomegalovirus ,Neumonitis ,Infection ,Pneumonitis ,Alcoholic ,Hepatitis - Abstract
La infección por citomegalovirus en pacientes inmunocompetentes suele ser asintomática. Los pacientes inmunodeprimidos pueden presentar cuadros severos con mala respuesta al tratamiento. Presentamos el caso de un paciente alcohólico con infección diseminada por citomegalovirus con excelente respuesta al tratamiento con ganciclovir. Usually, cytomegalovirus infection dosen’t cause symtons in immunocompetents patients although sometimes can. In alcoholic and cirrhotic subjects can cause several and fatal infections. We describe a case of disseminated cytomegalovirus infection in an alcoholic patient with excellent response to ganciclovir.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.